Expression, prognostic value and function of LMBR1L in gastric cancer

Gastric cancer remains a leading cause of cancer-related death worldwide, and effective prognostic biomarkers are urgently needed to guide clinical management. This study aimed to investigate the role of LMBR1L in gastric cancer. The expression of LMBR1L protein was detected by immunohistochemistry, Western blot and other methods. An LMBR1L knockdown HGC-27 cell line was constructed, and a xenograft experiment in nude mice was conducted to verify its effect on tumor growth in vivo. In addition, a nomogram model was constructed based on the expression level of LMBR1L and other clinical indicators to evaluate its predictive value for postoperative survival of gastric cancer patients. LMBR1L was highly expressed in gastric cancer. Patients with high expression of LMBR1L had lower postoperative overall survival (OS) and disease-free survival (DFS) rates than those with low expression. LASSO regression and Cox multivariate analysis showed that the expression level of LMBR1L was an independent risk factor for the prognosis of gastric cancer patients. The nomogram model constructed based on LMBR1L and other clinical indicators had a good predictive value for postoperative survival of gastric cancer patients, with areas under the ROC curve (AUC)of 0.642, 0.691 and 0.690 for 1-, 3- and 5-year survival rates, respectively. The xenograft experiment in nude mice indicated that knockdown of LMBR1L could significantly inhibit the development of gastric cancer in vivo. LMBR1L is highly expressed in gastric cancer and is closely related to poor prognosis of patients. Its regulatory effects on the biological behavior of gastric cancer in vitro and in vivo further confirm its important value as a prognostic biomarker and potential therapeutic target for gastric cancer, providing new insights into the molecular mechanisms of gastric cancer progression.